US2015080441A1PendingUtilityA1

Use of rasagiline for the treatment of restless legs syndrome

66
Assignee: BLAUGRUND ERANPriority: Apr 3, 2006Filed: Oct 27, 2014Published: Mar 19, 2015
Est. expiryApr 3, 2026(expired)· nominal 20-yr term from priority
Inventors:Eran BlaugrundRuth Levy
A61P 43/00A61P 25/08A61P 25/00A61P 25/14A61P 21/00A61K 31/428A61K 31/16A61K 2300/00A61K 31/135
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are methods for the treatment of Restless Legs Syndrome comprising administering an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising in unit dosage form R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof and pramipexole. 
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the amount of R(+)-N-propargyl-1-aminoindan or of the pharmaceutically acceptable salt thereof is from 0.5 mg to 5 mg. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the amount of R(+)-N-propargyl-1-aminoindan is 1 mg. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the R(+)-N-propargyl-1-aminoindan is the pharmaceutically acceptable salt of R(+)-N-propargyl-1-aminoindan. 
     
     
         5 . The pharmaceutical composition of  claim 4 , wherein the pharmaceutically acceptable salt is esylate, mesylate, sulfate or tartrate. 
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein the pharmaceutically acceptable salt is mesylate. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein the amount of R(+)-N-propargyl-1-aminoindan mesylate is 1.66 mg. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the amount of pramipexole is from 0.125 mg to 0.6 mg. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein the amount of pramipexole is from 0.375 mg to 6.0 mg. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the amount of pramipexole is 0.6 mg. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein the pramipexole is in a pharmaceutically acceptable salt form. 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein the pharmaceutically acceptable salt form is pramipexole dihydrochloride. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein the amount of pramipexole dihydrochloride is 0.6 mg. 
     
     
         14 . The pharmaceutical composition of  claim 12 , wherein the amount of pramipexole dihydrochloride is 0.75 mg. 
     
     
         15 . The pharmaceutical composition of  claim 3 , wherein the amount of pramipexole is from 0.125 mg to 0.6 mg. 
     
     
         16 . The pharmaceutical composition of  claim 3 , wherein the amount of pramipexole is from 0.375 mg to 6.0 mg. 
     
     
         17 . The pharmaceutical composition of  claim 15 , wherein the amount of pramipexole is 0.6 mg. 
     
     
         18 . The pharmaceutical composition of  claim 3 , wherein the pramipexole is in a pharmaceutically acceptable salt form. 
     
     
         19 . The pharmaceutical composition of  claim 18 , wherein the pharmaceutically acceptable salt form is pramipexole dihydrochloride. 
     
     
         20 . The pharmaceutical composition of  claim 19 , wherein the amount of pramipexole dihydrochloride is 0.6 mg. 
     
     
         21 . The pharmaceutical composition of  claim 19 , wherein the amount of pramipexole dihydrochloride is 0.75 mg.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.